Home › NDC Lookup › Ingredients › Fluocinonide › 70710-1284-03
🧴image loading
(from DailyMed)

Fluocinonide .5 mg/mL Solution, 60 mL — NDC 70710-1284-3 (Billing 70710-1284-03)

by Zydus Pharmaceuticals USA Inc. · 60 mL in 1 BOTTLE

This is a package of 60 mL of Fluocinonide .5 mg/mL Solution from Zydus Pharmaceuticals USA Inc., marketed since Nov 2018 and currently FDA-listed; retail pharmacies pay about $0.2049 per mL (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 70710-1284-03
🏷️ FDA NDC (as labeled) 70710-1284-3 billing pads the package segment with a zero
This package
Contains60 mL Cost per mL$0.2049 NADAC Per package$12.29 / 60 ml Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.3778/unit · Part D plans $0.4094/unit — full pricing hub ↓
Main listing for product 70710-1284 · Also comes in: 20 ml 70710-1284-8
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 70710-1284-3 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
70710 labeler · 1284 product · 3 package
Package marketed since
Nov 1, 2018
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
60 mL per package
Barcode (UPC)
0370710128432
Medicaid fills, this package
24,887 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Fluocinonide (different manufacturers) — 3 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Mar 25, 2026 — Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing. (SUN PHARMACEUTICAL INDUSTRIES INC) · FDA recall D-0476-2026
Class II · Mar 25, 2026 — Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing. (SUN PHARMACEUTICAL INDUSTRIES INC) · FDA recall D-0477-2026
Class II · Mar 25, 2026 — Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing. (SUN PHARMACEUTICAL INDUSTRIES INC) · FDA recall D-0475-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70710-1284-3
Product NDC 70710-1284
11-digit billing NDC 70710128403
NCPDP billing unit ML — per mL (volume)
RxCUI 310364
UNII 2W4A77YPAN
UPC 0370710128432
Application # ANDA208948
SPL Set ID 73315c87-4e55-41ea-883b-23d504c1b10d
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2018-11-01
Route TOPICAL
Dosage form SOLUTION
Substance FLUOCINONIDE
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90550060002005
GPI class Fluocinonide
GCN Seq No 007618
GCN 31401
HICL code 003318
Ingredient (HICL) Fluocinonide
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5P
Therapeutic class — specific (HIC3) Topical Anti-Inflammatory Steroidal
AHFS code 84:06.08.00
AHFS class Corticosteroids (Skin, Mucous Membrane)
FDB label name FLUOCINONIDE 0.05% SOLUTION
FDB brand name Fluocinonide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007618
  • GCN: 31401
  • GPI-14 (Medi-Span): 90550060002005
  • HICL (First Databank): 003318
  • AHFS class code: 84:06.08.00
  • RxCUI (RxNorm): 310364
Why two NDCs? The FDA registers this code as 70710-1284-3 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70710-1284-03. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids, Corticosteroids, potent (group III)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name FLUOCINONIDE 0.05% SOLUTION Ingredient Fluocinonide
📗 Our plain-language guide HelloPharmacist
  • It calms redness, swelling and itching from skin conditions that respond to steroids. The 0.1% creams, including Vanos, are for people 12 and older, and the label specifically desc...
  • Use a thin layer on the affected skin only. Follow the schedule on your label and from your prescriber, which differs between the 0.1% creams and the 0.05% products. Don't cover th...
  • No. The 0.1% creams are not for the face, groin or underarms. Also keep all of it out of your eyes, mouth and vagina.
  • The 0.1% creams are not recommended beyond 2 consecutive weeks. Stop once the condition is controlled, and tell your doctor if you see no improvement in 2 weeks.
📖 Read our full Fluocinonide guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.205 $12.29 / 60 ml
Medicaid paysCMS SDUD · 12 mo $0.3778 $22.67 / 60 ml
Medicare drug plans payPart D · Q2 2026 $0.4094 $24.56 / 60 ml
NADAC price history (per mL) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.424 $0.199
▼ Down 52% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
70710-1284-03 You're viewing this Main listing 60 mL in 1 BOTTLE $0.2049 / mL $12.29 2018-11-01 — Active
70710-1284-08 70710-1284-8 20 mL in 1 BOTTLE — — 2018-11-01 — Active

You're viewing the largest of 2 pack sizes for this product.

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 60 mL — 60 ml in 1 bottle.
How does this package differ from NDC 70710-1284-08?
Both are Fluocinonide .5 mg/mL Solution — the drug itself is identical. This page's package is the 60 mL one, while NDC 70710-1284-08 is the 20 ml package.
What NDC number is used to bill for this package of Fluocinonide .5 mg/mL Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
fluocinonide .5 mg/mL 00168-0134-60 E. 1 bottle $0.205 AT Availability likely —
Fluocinonide .5 mg/mL 21922-0001-01 Encube 1 bottle $0.205 AT Availability likely —
Fluocinonide .5 mg/mLthis 70710-1284-03 Zydus 60 ml $0.205 AT Availability likely —
Fluocinonide .5 mg/mL 70752-0154-05 QUAGEN 1 bottle $0.205 AT Availability likely —
Fluocinonide .5 mg/mL 72603-0703-01 NorthStar 1 bottle $0.205 AT Availability likely —
Fluocinonide .5 mg/mL 33342-0320-84 Macleods 1 bottle $0.314 AT Availability likely +53%
Fluocinonide .5 mg/mL 43386-0026-02 Lupin 1 bottle $0.314 AT Availability likely +53%
Fluocinonide .5 mg/mL 51672-1273-02 Sun 1 bottle $0.314 AT Availability likely +53%
fluocinonide .5 mg/mL 40032-0026-06 Novel 1 bottle — AT FDA listed —
Fluocinonide .5 mg/mL 63629-9583-01 Bryant 1 bottle — AT FDA listed —
Fluocinonide .5 mg/mL 68071-3918-06 NuCare 1 bottle — AT FDA listed —
Fluocinonide .5 mg/mL 70771-1375-03 Zydus 60 ml — AT FDA listed —
Fluocinonide .5 mg/mL 71656-0094-20 Saptalis 20 ml — AT FDA listed —
Fluocinonide .5 mg/mL 72162-1270-06 Bryant 1 bottle — AT FDA listed —
fluocinonide .5 mg/mL 72162-2146-06 Bryant 1 bottle — AT FDA listed —
Fluocinonide .5 mg/mL 72162-2490-02 Bryant 1 bottle — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2018
On the market since
Nov 2018
📍
2026
Currently FDA-listed
8 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Fluocinonide inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3K9958V90M
    A liquid solvent derived from fermentation or chemical synthesis. In medicines, alcohol dissolves active ingredients, helps preserve the product, and improves how the body absorbs certain drugs.
  • UNII 2968PHW8QP
    A weak organic acid derived from citrus fruits or made through fermentation. It works as a buffer to control pH, a preservative to extend shelf life, and a flavoring agent in medications.
  • UNII P7E6YFV72X
    Diisopropyl adipate is a clear, oily liquid derived from adipic acid. It acts as a plasticizer and solvent in medicines, helping soften coatings and improve how the drug dissolves or spreads in the body.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerZydus Pharmaceuticals USA Inc.
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA208948 (ANDA)
Labeler code70710
First marketedNov 2018
Product typeHuman Prescription Drug
Portfolio454 products on file

More NDCs from Zydus Pharmaceuticals USA Inc. labeler code 70710

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 🍼 Nursing Mothers 🧬 Pharmacokinetics 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 22 words ▾

INDICATIONS AND USAGE Fluocinonide topical solution USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

⏱️ Dosage and Administration 62 words ▾

DOSAGE AND ADMINISTRATION Fluocinonide topical solution USP, 0.05% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

⛔ Contraindications 21 words ▾

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

🤒 Adverse Reactions 59 words ▾

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria

🧒 Pediatric Use 114 words ▾

Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.

Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

🆘 Overdosage 17 words ▾

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS .)

🧬 Clinical Pharmacology 210 words ▾

CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.

There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. A significantly greater amount of fluocinonide is absorbed from the solution than from the cream or gel formulations.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids.

Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See DOSAGE AND ADMINISTRATION .) Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees.

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📦 How Supplied / Storage and Handling 77 words ▾

HOW SUPPLIED Fluocinonide Topical Solution USP, 0.05% is clear solution free from particulate matter and is supplied as: NDC 70710-1284-8 in bottle of 20 mL NDC 70710-1284-3 in bottle of 60 mL Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat, above 40°C (104°F). Call your doctor for medical advice about side effects.

You may report side effects to FDA at 1-800-FDA-1088. Please address medical inquiries to, ([email protected]) Tel.: 1-877-993-8779.

📋 Description 125 words ▾

DESCRIPTION Fluocinonide topical solution USP, 0.05% is intended for topical administration. The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4 -diene-3,20 -dione,21-(acetyloxy)-6 ,9 -difluoro -11-hydro xy-16 ,17-[(1- methylethylidene)bis(oxy)]-,(6 α, 11β, 16 α)-. It has the following chemical structure: Fluocinonide, USP is white or almost white microcrystalline powder.

It is practically insoluble in water, very slightly soluble in ether, slightly soluble in ethanol, methanol and dioxane, sparingly soluble in acetone and chloroform. Fluocinonide topical solution USP, 0.05% contains fluocinonide USP, 0.5 mg/mL in a solution of citric acid monohydrate, dehydrated alcohol (35%), diisopropyl adipate, propylene glycol and purified water. In this formulation, the active ingredient is totally in solution.

Fluocinonide topical solution USP, 0.5%

⚠️ Precautions ~3 min read ▾

PRECAUTIONS General Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, the addition of occlusive dressings, and dosage form. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests.

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See PRECAUTIONS - Pediatric Use .) This preparation is not for ophthalmic use. Severe irritation is possible if fluocinonide solution contacts the eye.

If that should occur, immediate flushing of the eye with a large volume of water is recommended. If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues.

When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

If there is contact with the eyes and severe irritation occurs, immediately flush with a large volume of water. Patients should be advised not to use this medication for any disorder other than for which it was prescribed. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.

Patients should report any signs of local adverse reactions especially under occlusive dressing. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings. Laboratory Tests The following tests may be helpful in evaluating the HPA axis suppression: Urinary free cortisol test ACTH stimulation test Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results. Pregnancy Category C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.

There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amoun… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 58 words ▾

Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

🧬 Pharmacokinetics 150 words ▾

Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. A significantly greater amount of fluocinonide is absorbed from the solution than from the cream or gel formulations. Topical corticosteroids can be absorbed from normal intact skin.

Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.

(See DOSAGE AND ADMINISTRATION .) Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📄 Package Label / Principal Display Panel 27 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70710-1284-3 Fluocinonide topical solution USP, 0.05% Rx only 60 mL Zydus Fluocinonide topical solution USP, 0.5% image Fluocinonide topical solution USP, 0.05%

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
24.9K
Units reimbursed last 4 qtrs
1.6M
Gross reimbursed last 4 qtrs
$587.1K
Avg / prescription
$23.59
Avg / unit
$0.3778
Latest quarter Q1 2026
5.9KRx
Medicaid pays / mL
$0.3778
gross reimbursed
vs
NADAC / mL
$0.2049
acquisition cost
=
Spread
+$0.1729
+84% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
53% FFS 47% MCO
Fee-for-service · 13,169 Rx Managed care · 11,718 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 10,020 units · 128 per 100k residents WA Idaho: 5,660 units · 288 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 81,810 units · 1,426 per 100k residents MN Wisconsin: 22,280 units · 377 per 100k residents WI Michigan: 38,400 units · 383 per 100k residents MI New York: 151,780 units · 776 per 100k residents NY Vermont: 3,480 units · 538 per 100k residents VT New Hampshire: 4,080 units · 291 per 100k residents NH Oregon: 28,020 units · 662 per 100k residents OR Nevada: 21,820 units · 683 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 15,420 units · 481 per 100k residents IA Illinois: 98,200 units · 783 per 100k residents IL Indiana: 22,500 units · 328 per 100k residents IN Ohio: 122,910 units · 1,043 per 100k residents OH Pennsylvania: 22,700 units · 175 per 100k residents PA New Jersey: no data reported NJ Massachusetts: 26,340 units · 376 per 100k residents MA California: 512,960 units · 1,316 per 100k residents CA Utah: 9,180 units · 269 per 100k residents UT Colorado: 31,740 units · 540 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 24,600 units · 544 per 100k residents KY West Virginia: no data reported WV Virginia: 5,280 units · 60.6 per 100k residents VA Maryland: 28,620 units · 463 per 100k residents MD Connecticut: 3,240 units · 89.6 per 100k residents CT Rhode Island: 5,100 units · 466 per 100k residents RI Arizona: 22,240 units · 299 per 100k residents AZ New Mexico: 13,740 units · 650 per 100k residents NM Kansas: 2,880 units · 98.0 per 100k residents KS Arkansas: no data reported AR Tennessee: 46,560 units · 653 per 100k residents TN North Carolina: 37,800 units · 349 per 100k residents NC South Carolina: 6,360 units · 118 per 100k residents SC Delaware: no data reported DE Oklahoma: 27,560 units · 680 per 100k residents OK Louisiana: 7,320 units · 160 per 100k residents LA Mississippi: 1,980 units · 67.3 per 100k residents MS Alabama: 8,760 units · 171 per 100k residents AL Georgia: 32,420 units · 294 per 100k residents GA D.C.: 720 units · 106 per 100k residents DC Hawaii: 3,660 units · 255 per 100k residents HI Texas: 19,980 units · 65.5 per 100k residents TX Florida: 26,040 units · 115 per 100k residents FL
Units reimbursed · per 100k residents
60.61,426
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Minnesota 1,426 /100k
2 California 1,316 /100k
3 Ohio 1,043 /100k
4 Illinois 783 /100k
5 New York 776 /100k
6 Nevada 683 /100k
7 Oklahoma 680 /100k
8 Oregon 662 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
60 ml this page70710-1284-03 24,887 Rx · $587,102
20 ml70710-1284-08 No Medicaid data
Drug total (last 4 qtrs): 24,887 Rx · 1,554,160 units · $587,102 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Fluocinonide — the program that covers self-administered drugs. 13 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Fluocinonide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$6.96M
Claims incl. refills
176.2K
Beneficiaries
135.8K
Spend / beneficiary
$51.22
Spend / claim
$39.49
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Fluocinonide — the ingredient across all brands.

Top reported reactions

Psoriasis546
Rash454
Pruritus426
Fatigue288
Diarrhoea285
Nausea275
Pain273

Age at onset

Infant3
Child69
Adolescent77
Adult980
Elderly477

Reporter sex

5,595 reports

Serious outcomes

Hospitalization1,022
Death259
Disabling99
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 438 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 70710-1277-01 · Zydus 70710-1285-00 · Zydus →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.